CAR-T Cell Therapy in Solid Tumor
DOI:
https://doi.org/10.54097/srya2x22Keywords:
CAR-T; solid tumor; immunity.Abstract
Chimeric antigen receptor (CAR) T cell immunotherapy has gained significant popularity in recent years as a promising approach for cancer treatment. This form of immunotherapy involves the genetic modification of T cells to enable them to recognize and attack cancer cells within the body. Despite the advancements in CAR-T cell therapy and related technologies, several challenges persist in the field of solid tumor research. These challenges include antigen escape, off-target effects, and the complex immune microenvironment. This study aims to evaluate the advantages and drawbacks of CAR-T cell therapy specifically in the context of solid tumors, shedding light on potential avenues for further development. Furthermore, the application of CAR-T cell treatment in solid tumors, such as breast cancer, is discussed. The study also addresses various limitations associated with CAR-T cell therapy, including the influence of the immune microenvironment and the potential for antigen evasion. In addition, the study explores future directions for CAR-T cell therapy, highlighting the potential role of synthetic biology. By examining these aspects, this research aims to contribute to the understanding of CAR-T cell treatment and provide valuable insights to combat solid tumors effectively.
Downloads
References
Cao Yuhuan, Yuan Xueli. Application of CAR-T cells in the treatment of solid tumors [J]. Medical Review, 2020, 26(23): 4634-4642. (in Chinese)
Liu Jiao, Tu Xiaoxuan, LIU Lulu, Fang Weijia. New progress of chimeric antigen receptor T cells in the treatment of malignant solid tumors [J]. Journal of Zhejiang University: Medical Edition, 2022, 51(2): 175-184. (in Chinese)
LI J, LI W, HUANG K, et al. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward[J]. J Hematol Oncol, 2018, 11(1): 22.
ZHANG Cheng, Deng Yang, Sun Dandan, Xu Chengchen, Zhou Jun. Research status and prospect of CAR-T cell immunotherapy in solid tumors [J]. Chinese Science and Technology Journal Database Citation Edition Medicine and Health, 2021(3): 244-245. (in Chinese)
Lum, L.G., et al. Phase II clinical trial using anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) for HER2-negative (0-2+) metastatic breast cancer[J]. Journal of Clinical Oncology, 2019, 37(15): 1080.
Du Li. Study on optimal strategy of chimeric antigen receptor T cell therapy [D]. Chongqing medical university, 2022. DOI: 10.27674 /, dc nki. Gcyku. 2021.000036.
Dang Kechun, Wang Jinwei. Challenges and strategies of CAR-T cell therapy for solid tumors [J]. Pharmaceutical and Clinical Research, 2022, 30(6): 529-535. (in Chinese)
YAO Zheng, LI Zihan, GAO Liming, Hu Xing, Chen Yan, Pan Wenqi, Li Qian. Research progress of CAR-T cell immunotherapy for solid tumors [J]. Journal of China Pharmaceutical University, 2021, 52(4): 496-504. (in Chinese)
Du X. Dimensional reduction: Chinese enterprises explore a new approach to CAR-T therapy for solid tumors [J]. Zhang Jiang Science and Technology Review, 2023(2): 20-23.
Shi Tianyu, Meng Fanyan. Research progress of CAR-T cells in the treatment of solid tumors based on synthetic biology [J]. Chinese Journal of Cancer Biotherapy, 2023, 30(03): 261-266.
ALLEN G M, FRANKEL N W, REDDY N R, et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors[J]. Science, 2022, 378(6625): eaba1624 [2022-12-10]. Available from: https://pubmed.ncbi.nlm.nih.gov/36520915/.
YANG M J, TANG X, ZHANG Z L, et al. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors[J]. Theranostics, 2020, 10(17): 7622-7634.
SUN Z C, LI R T, SHEN Y, et al. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







